These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 1570858)

  • 1. Projecting future drug expenditures--1992.
    Ensor PA
    Am J Hosp Pharm; 1992 Jan; 49(1):140-5. PubMed ID: 1570858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting future drug expenditures--1993.
    Santell JP
    Am J Hosp Pharm; 1993 Jan; 50(1):71-7. PubMed ID: 8427283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Projecting future drug expenditures--1994.
    Santell JP
    Am J Hosp Pharm; 1994 Jan; 51(2):177-87. PubMed ID: 8160668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Projecting future drug expenditures--1996.
    Santell JP
    Am J Health Syst Pharm; 1996 Jan; 53(2):139-50. PubMed ID: 8653479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting future drug expenditures--2002.
    Shah ND; Vermeulen LC; Santell JP; Hunkler RJ; Hontz K
    Am J Health Syst Pharm; 2002 Jan; 59(2):131-42. PubMed ID: 11826567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Points to consider about prescription drug prices: an overview of federal policy and pricing studies.
    Kucukarslan S; Hakim Z; Sullivan D; Taylor S; Grauer D; Haugtvedt C; Zgarrick D
    Clin Ther; 1993; 15(4):726-38. PubMed ID: 8221823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984.
    Hogan GF
    Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of multiple-source entry on price competition after patent expiration in the pharmaceutical industry.
    Suh DC; Manning WG; Schondelmeyer S; Hadsall RS
    Health Serv Res; 2000 Jun; 35(2):529-47. PubMed ID: 10857475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projecting future drug expenditures--1999.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1999 Jan; 56(1):31-9. PubMed ID: 10048877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2009 Jul; 74(143):37163-8. PubMed ID: 19655468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do pharmaceutical prices respond to potential patient out-of-pocket expenses?
    Pavenik N
    Rand J Econ; 2002; 33(3):469-87. PubMed ID: 12585303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Projecting future drug expenditures--2006.
    Hoffman JM; Shah ND; Vermeulen LC; Schumock GT; Grim P; Hunkler RJ; Hontz KM
    Am J Health Syst Pharm; 2006 Jan; 63(2):123-38. PubMed ID: 16390926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic pharmaceutical prices continue their decline in prices from last year.
    Hosp Mater Manage; 1996 Feb; 21(2):1, 12-3. PubMed ID: 10154299
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of a generic substitution reform on patients' and society's expenditure for pharmaceuticals.
    Andersson K; Bergström G; Petzold MG; Carlsten A
    Health Policy; 2007 May; 81(2-3):376-84. PubMed ID: 16945449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why drug prices will go lower.
    Tully S
    Fortune; 1993 May; 127(9):56-8, 60, 62 passim. PubMed ID: 10125261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Projecting future drug expenditures--1997.
    Mehl B; Santell JP
    Am J Health Syst Pharm; 1997 Jan; 54(2):153-61. PubMed ID: 9117803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.